SMAGALS, or Stop Myelin-Associated Glycoprotein for Amyotrophic Lateral Sclerosis, is a futuristic combination of drugs and a pump that will help to improve the quality of life for ALS patients, hopefully, by 2023. Much of the current research for ALS is still in the hypothetical stages and has not yet been tested on humans. We merged ideas from several medical school research groups with a unique molecular cleavage mechanism and a pump to create SMAGALS.
In 1985, the C60 buckminsterfullerene was discovered. See the blue model of the buckyball on the left. Although in the past, most applications of this molecule had been almost exclusively in engineering, now it is also used in biology. C60 spheres ("buckyballs") have been modified by the addition of three axial, or equatorial, malonic acid groups per molecule, and are a potentially powerful "free radical sponge." The buckyball becomes water-soluble when it is chemically modified by the addition of the acid groups. Research shows that the carboxyfullerenes are neuroprotective in cell culture.
When tested in the transgenic model of familial ALS, the carboxyfullerene with axially oriented malonic acid groups best delayed the onset of disease and extended survival. The prolongation of survival rate was about the same as that seen previously with Riluzole, which is thought to act through the inhibition of excitatory neurotransmission. Thus, water-soluble buckyballs may prove to be useful neuroprotective agents. We created SMAGALS to use the malonic groups attached to the buckyball to make it soluble in the spinal fluid. The buckyball will deliver a new antibody for ALS therapy.
Since 2000, scientists have identified and modeled the plausible binding site for a C60 fullerene to an antibody. The massive antibody covers approximately 90% of the surface of the buckyball, nearly burying the fullerene. Our prototype is displayed in the picture on the right. Complete descriptions of the exact geometry of the fullerene-antibody linkage have not been determined yet. SMAGALS uses a link between the buckminsterfullerene and the antibody that is sensitive to 600 nanometers (nm) of wavelength. The bonding sites between the buckyball and antibody contain very sensitive linkers that will break, due to energy transfer (ET). This energy transfer will be sufficient to cause the bonds between the buckyball and the antibody to break and free the antibody to stop the myelin-associated glycoprotein (MAG) from working in the body.
An implantable, programmable, battery-powered pump will deliver the buckyballs into the spinal fluid. This pump will be placed near the waist, in the back of the patient. A computer program will operate the delivery of the drugs. Similar pumps are now used to help people with chronic back pain. The buckyball pump (BP) will deliver C60 molecules, as it is linked to an antibody as well as a designer molecule. The BP will be programmed to deliver a designer molecule that has absorbed two or three 800 nm photons from the IR diode as the molecules pass through the pump. ET will occur at about 600 nm when the designer molecules are near the buckyball-antibody linkage.
The new antibody for SMAGALS blocks myelin-associated glycoprotein (MAG). Recent research has already identified these glycoprotein molecules, which have inhibiting effects on nerve regeneration. The SMAGALS antibody will block MAG, neutralizing these inhibitors and helping nerve regeneration. Normally, the body controls the number of contacts nerve cells make by not letting new connections be made. When the spine is injured, the body needs to repair the nerve cells and its long axons, and so the chemicals in the body that stops regeneration of nerves needs to be shut down. MAG is one of the “stop signs” in the body; SMAGALS is designed to make MAG ineffective. This allows the body to regenerate new myelin wrappings around the nerve cells. Since ALS is a disease that gradually destroys myelin cells, this method of stopping MAG will greatly benefit people who suffer from ALS.
SMAGALS is a futuristic approach to promote a better quality of life for patients with ALS. It is NOT a cure. Since the cause of the disease is still unknown, one can only approach the problem by interfering with one of the proposed mechanisms in the body. SMAGALS uses up-to-date research and then projects these ideas into technologies that might be feasible by the year 2023. Using the C60 molecule to trap free radicals, as well as making it a vehicle to move the new antibody into the spinal fluid is a potentially wonderful technology to help defeat ALS. The buckyball pump delivers the photosensitive linkage between the buckyball and antibody, and a designer molecule that absorbs IR photons. Inhibiting the work of MAG by the new antibody allows the body to regenerate nerve cells. The motor neurons will begin to function and let the person use his/her limbs.
Below is a Quicktime movie clip that shows the photon (laser light) as it breaks the linkage between the buckyball and antibody: